

Nr.	Numele studiului	Status	Locatia/Locatiile studiului
1	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)	In curs de recrutare	<ul style="list-style-type: none"> • Bucharest, Romania, 10825, Contact: Contact 1-888-EXELIXIS (888-393-5494) • Bucharest, Romania, 11863, Contact: Contact 1-888-EXELIXIS (888-393-5494) • Cluj-Napoca, Romania, 400058, Contact: Contact 1-888-EXELIXIS (888-393-5494) • Cluj-Napoca, Romania • Timisoara, Romania, 300723
2	A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy	In curs de recrutare	<ul style="list-style-type: none"> • Exelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015 • Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385 • Exelixis Clinical Site #142, Timișoara, Timis, Romania, 300166 • Exelixis Clinical Site #146, Bucuresti, Romania, 011863
3	A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile	Activ, inca nu se recruteaza	<ul style="list-style-type: none"> • Facility #1, Cluj-Napoca, Cluj, Romania, 400058 • Facility #1, Bucharest, Romania, 11863
4	An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer	Activ, inca nu se recruteaza	<ul style="list-style-type: none"> • Investigational Site Number 1801, Bucharest, Romania